EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
As Merck & Co’s Keynote-361 study fails, attention turns to Bavencio’s Asco late-breaker and the potential of Padcev.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.